Annual CFO
-$70.83 M
-$5.68 M-8.73%
31 December 2023
Summary:
Immunic annual cash flow from operations is currently -$70.83 million, with the most recent change of -$5.68 million (-8.73%) on 31 December 2023. During the last 3 years, it has fallen by -$24.70 million (-53.56%). IMUX annual CFO is now -804.46% below its all-time high of -$7.83 million, reached on 31 December 2011.IMUX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$20.80 M
-$3.77 M-22.15%
30 September 2024
Summary:
Immunic quarterly cash flow from operations is currently -$20.80 million, with the most recent change of -$3.77 million (-22.15%) on 30 September 2024. Over the past year, it has dropped by -$3.49 million (-20.17%). IMUX quarterly CFO is now -356.71% below its all-time high of -$4.55 million, reached on 31 March 2013.IMUX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$75.83 M
-$3.49 M-4.83%
30 September 2024
Summary:
Immunic TTM cash flow from operations is currently -$75.83 million, with the most recent change of -$3.49 million (-4.83%) on 30 September 2024. Over the past year, it has dropped by -$3.92 million (-5.46%). IMUX TTM CFO is now -1564.76% below its all-time high of -$4.55 million, reached on 31 March 2013.IMUX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMUX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.7% | -20.2% | -5.5% |
| 3 y3 years | -53.6% | -18.2% | -3.1% |
| 5 y5 years | -64.1% | -248.1% | -181.6% |
IMUX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -53.6% | +14.9% | -53.0% | +13.2% | -18.5% | +16.6% |
| 5 y | 5 years | -148.1% | +14.9% | -248.1% | +28.3% | -181.6% | +16.6% |
| alltime | all time | -804.5% | +14.9% | -356.7% | +28.3% | -1564.8% | +16.6% |
Immunic Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.80 M(+22.1%) | -$75.83 M(+4.8%) |
| June 2024 | - | -$17.03 M(-28.9%) | -$72.34 M(-3.9%) |
| Mar 2024 | - | -$23.97 M(+70.9%) | -$75.28 M(+6.3%) |
| Dec 2023 | -$70.83 M(+8.7%) | -$14.03 M(-19.0%) | -$70.83 M(-1.5%) |
| Sept 2023 | - | -$17.31 M(-13.3%) | -$71.91 M(+5.4%) |
| June 2023 | - | -$19.98 M(+2.4%) | -$68.19 M(+6.6%) |
| Mar 2023 | - | -$19.51 M(+29.2%) | -$63.98 M(-1.8%) |
| Dec 2022 | -$65.14 M(-21.7%) | -$15.10 M(+11.1%) | -$65.14 M(-11.6%) |
| Sept 2022 | - | -$13.60 M(-13.7%) | -$73.72 M(-5.2%) |
| June 2022 | - | -$15.76 M(-23.8%) | -$77.72 M(-14.6%) |
| Mar 2022 | - | -$20.68 M(-12.7%) | -$90.97 M(+9.3%) |
| Dec 2021 | -$83.23 M(+80.5%) | -$23.68 M(+34.6%) | -$83.23 M(+13.2%) |
| Sept 2021 | - | -$17.60 M(-39.3%) | -$73.52 M(+8.4%) |
| June 2021 | - | -$29.00 M(+124.0%) | -$67.82 M(+41.2%) |
| Mar 2021 | - | -$12.95 M(-7.3%) | -$48.04 M(+4.2%) |
| Dec 2020 | -$46.12 M(+61.6%) | -$13.96 M(+17.3%) | -$46.12 M(+20.0%) |
| Sept 2020 | - | -$11.90 M(+29.0%) | -$38.43 M(+18.2%) |
| June 2020 | - | -$9.23 M(-16.3%) | -$32.50 M(-5.1%) |
| Mar 2020 | - | -$11.03 M(+76.0%) | -$34.26 M(+20.0%) |
| Dec 2019 | -$28.55 M(-33.9%) | -$6.26 M(+4.8%) | -$28.55 M(+6.0%) |
| Sept 2019 | - | -$5.98 M(-45.6%) | -$26.93 M(-20.9%) |
| June 2019 | - | -$10.99 M(+106.6%) | -$34.04 M(-3.9%) |
| Mar 2019 | - | -$5.32 M(+14.3%) | -$35.41 M(-18.0%) |
| Dec 2018 | -$43.16 M | -$4.65 M(-64.4%) | -$43.16 M(-10.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$13.08 M(+5.9%) | -$48.43 M(+8.2%) |
| June 2018 | - | -$12.36 M(-5.5%) | -$44.77 M(+5.2%) |
| Mar 2018 | - | -$13.07 M(+31.8%) | -$42.56 M(+5.4%) |
| Dec 2017 | -$40.40 M(+12.9%) | -$9.92 M(+5.3%) | -$40.40 M(+2.1%) |
| Sept 2017 | - | -$9.42 M(-7.2%) | -$39.58 M(+4.0%) |
| June 2017 | - | -$10.15 M(-7.0%) | -$38.05 M(+3.6%) |
| Mar 2017 | - | -$10.91 M(+19.9%) | -$36.73 M(+2.7%) |
| Dec 2016 | -$35.77 M(-28.4%) | -$9.10 M(+15.4%) | -$35.77 M(-0.5%) |
| Sept 2016 | - | -$7.89 M(-10.6%) | -$35.96 M(-10.3%) |
| June 2016 | - | -$8.83 M(-11.3%) | -$40.11 M(-13.6%) |
| Mar 2016 | - | -$9.96 M(+7.2%) | -$46.40 M(-7.1%) |
| Dec 2015 | -$49.95 M(+22.4%) | -$9.29 M(-22.8%) | -$49.95 M(-2.2%) |
| Sept 2015 | - | -$12.04 M(-20.4%) | -$51.05 M(+1.7%) |
| June 2015 | - | -$15.12 M(+11.9%) | -$50.21 M(+11.7%) |
| Mar 2015 | - | -$13.51 M(+30.0%) | -$44.97 M(+10.1%) |
| Dec 2014 | -$40.83 M(+42.5%) | -$10.39 M(-7.1%) | -$40.83 M(+0.6%) |
| Sept 2014 | - | -$11.19 M(+13.3%) | -$40.57 M(+8.2%) |
| June 2014 | - | -$9.88 M(+5.5%) | -$37.48 M(+12.0%) |
| Mar 2014 | - | -$9.36 M(-7.6%) | -$33.46 M(+16.8%) |
| Dec 2013 | -$28.65 M(+209.9%) | -$10.13 M(+25.1%) | -$28.65 M(+54.7%) |
| Sept 2013 | - | -$8.10 M(+38.4%) | -$18.51 M(+77.9%) |
| June 2013 | - | -$5.85 M(+28.5%) | -$10.41 M(+128.5%) |
| Mar 2013 | - | -$4.55 M | -$4.55 M |
| Dec 2012 | -$9.24 M(+18.0%) | - | - |
| Dec 2011 | -$7.83 M | - | - |
FAQ
- What is Immunic annual cash flow from operations?
- What is the all time high annual CFO for Immunic?
- What is Immunic annual CFO year-on-year change?
- What is Immunic quarterly cash flow from operations?
- What is the all time high quarterly CFO for Immunic?
- What is Immunic quarterly CFO year-on-year change?
- What is Immunic TTM cash flow from operations?
- What is the all time high TTM CFO for Immunic?
- What is Immunic TTM CFO year-on-year change?
What is Immunic annual cash flow from operations?
The current annual CFO of IMUX is -$70.83 M
What is the all time high annual CFO for Immunic?
Immunic all-time high annual cash flow from operations is -$7.83 M
What is Immunic annual CFO year-on-year change?
Over the past year, IMUX annual cash flow from operations has changed by -$5.68 M (-8.73%)
What is Immunic quarterly cash flow from operations?
The current quarterly CFO of IMUX is -$20.80 M
What is the all time high quarterly CFO for Immunic?
Immunic all-time high quarterly cash flow from operations is -$4.55 M
What is Immunic quarterly CFO year-on-year change?
Over the past year, IMUX quarterly cash flow from operations has changed by -$3.49 M (-20.17%)
What is Immunic TTM cash flow from operations?
The current TTM CFO of IMUX is -$75.83 M
What is the all time high TTM CFO for Immunic?
Immunic all-time high TTM cash flow from operations is -$4.55 M
What is Immunic TTM CFO year-on-year change?
Over the past year, IMUX TTM cash flow from operations has changed by -$3.92 M (-5.46%)